As coronavirus continues to spread across New York City, other virus hot spots are emerging across the country, including Detroit and New Orleans. These epicenters are seeing a surge in coronavirus patients but lack the medical supplies and staff to combat this growing crisis. But how exactly do these coronavirus epicenters come to be? And what does this mean for immunodeficient patients living in these places?
This week on the Patients Rising Podcast, we have part two of Dr. Bob’s interview with Dr. Hugh Rosen, who explains how and why these COVID-19 hotspots emerge. He also discusses experimental treatments for those who have contracted the virus.
Hugh Rosen, M.D., Ph.D. Professor of Molecular Medicine at The Scripps Research Institute’s California Campus and Chairman and President of ActivX Biosciences Inc.
Dr. Rosen has over 30 years of medical experience with a research focus on lymphocyte trafficking. His work at The Scripp’s Research Institute (TSRI) led to the development of ozanimod, which helps alleviate brain atrophy for patients with multiple sclerosis. Its benefits may also extend to those suffering from other autoimmune conditions.
Prior to his work at TSRI, Dr. Rosen served as the Executive Director of Immunology, Rheumatology, and Infectious Diseases at Merck Research Laboratories. He was also Chair of the Worldwide Business Strategy Team for Antibacterials and Antifungals.
Currently, Dr. Rosen serves on the Board of Directors at Regulus. In 2017, Dr. Rosen became the President and Chairman of ActivX Bioscience Inc., a biopharmeceutical company focused on the research and development of molecular drugs.
Dr. Rosen earned his M.D. from the University of Cape Town and his Ph.D. in Physiological Sciences from the University of Oxford.
Terry Wilcox, Executive Director, Patients Rising
Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.
Kate Pecora, Field Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: firstname.lastname@example.org
Professor of Molecular Medicine, Scripps Research Institute
With over 30 years of experience, Dr. Rosen's research has focused on lymphocyte trafficking. His work at The Scripp’s Research Institute led to the development of Ozanimod, a drug which helps alleviate brain atrophy for patients with multiple sclerosis, among other medications.